• Aucun résultat trouvé

Review of the current status of RAS mutation testing in patients with metastatic colorectal cancer (mCRC): Flash-RAS study

N/A
N/A
Protected

Academic year: 2021

Partager "Review of the current status of RAS mutation testing in patients with metastatic colorectal cancer (mCRC): Flash-RAS study"

Copied!
2
0
0

Texte intégral

Loading

Références

Documents relatifs

The differences in VEGFR1 phosphorylation were not linked to altered protein levels, as determined by ELISA of total VEGFR1 in tumor extracts (Supplementary Fig.. Influence

Furthermore, IdyllaTM is not able to reduce the time between request of the RAS test by physician and the receipt of tumour tissue by the molecular genetics platform that may be

[A retrospective observational study on KRAS and NRAS testing in 2014 in patients with metastatic colorectal cancer (mCRC).]. Thierry AR, Mouliere F, El Messaoudi S,

The prevalent KRAS c.35 G > A (G12D) mutant genotype has a significantly worse effect on the OS of MCRC pts treated with the first line FIr-B/FOx intensive regimen compared

Biomarkers are needed to guide the standard of care, such as adjuvant chemotherapy in stage III colon cancer or neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal

In conclusion, we identified activated EGFR and HER3 as biomarkers predictive for a better overall survival in patients treated by anti-EGFR therapy.. Response to treatment, on

This study was designed to evaluate KRAS genotyping in 40 French laboratories related to one of the 28 molecular genetics centers, using cell line and formalin-fixed

Cite this article as: Bruera et al.: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus